Chapter Twenty-Nine – Engineering Challenges in Immunobarrier Device Development

[1]  C. Colton,et al.  Effect of Hypoxia on Insulin Secretion by Isolated Rat and Canine Islets of Langerhans , 1993, Diabetes.

[2]  R. Schnettler,et al.  Alginate coating of islets of Langerhans: in vitro studies on a new method for microencapsulation for immuno-isolated transplantation , 2004, Acta Diabetologica.

[3]  N. Simpson,et al.  Effects of growth regulation on conditionally-transformed alginate-entrapped insulin secreting cell lines in vitro. , 2005, Biomaterials.

[4]  Clark K. Colton,et al.  CHAPTER 27 – ENGINEERING CHALLENGES IN IMMUNOISOLATION DEVICE DEVELOPMENT , 2000 .

[5]  A. Wernerson,et al.  Improved Survival of Macroencapsulated Islets of Langerhans by Preimplantation of the Immunoisolating Device: A Morphometric Study , 2003, Cell transplantation.

[6]  S. Bonner-Weir,et al.  In Situ Electrochemical Oxygen Generation with an Immunoisolation Device , 1999, Annals of the New York Academy of Sciences.

[7]  Tejal A Desai,et al.  Nanoporous microsystems for islet cell replacement. , 2004, Advanced drug delivery reviews.

[8]  P. de Vos,et al.  University of Groningen Factors influencing functional survival of microencapsulated islet grafts , 2004 .

[9]  Y. Bae,et al.  Prolonged Glucose Normalization of Streptozotocin-Induced Diabetic Mice by Transplantation of Rat Islets Coencapsulated with Crosslinked Hemoglobin , 2004, Transplantation.

[10]  R. van Schilfgaarde,et al.  Response of Encapsulated Rat Pancreatic Islets to Hypoxia , 2003, Cell transplantation.

[11]  I. Tannock,et al.  Oxygen diffusion and the distribution of cellular radiosensitivity in tumours. , 1972, The British journal of radiology.

[12]  Myriam Schluep,et al.  Intrathecal delivery of CNTF using encapsulated genetically modifiedxenogeneic cells in amyotrophic lateral sclerosis patients , 1996, Nature Medicine.

[13]  C. Colton,et al.  Bioengineering in development of the hybrid artificial pancreas. , 1991, Journal of biomechanical engineering.

[14]  C. Colton,et al.  Implantable biohybrid artificial organs. , 1995, Cell transplantation.

[15]  J. Bloch,et al.  Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons , 2004, Neurobiology of Disease.

[16]  B. Morsi,et al.  Gas-liquid mass-transfer and hydrodynamic parameters in a soybean oil hydrogenation process under industrial conditions , 2000 .

[17]  B. Hering,et al.  Inhibition of Cellular Immune Responses to Encapsulated Porcine Islet Xenografts by Simultaneous Blockade of Two Different Costimulatory Pathways , 2005, Transplantation.

[18]  Giovanni Luca,et al.  Grafts of microencapsulated pancreatic islet cells for the therapy of diabetes mellitus in non‐immunosuppressed animals , 2004, Biotechnology and applied biochemistry.

[19]  P. Brunetti,et al.  Standard technical procedures for microencapsulation of human islets for graft into nonimmunosuppressed patients with type 1 diabetes mellitus. , 2006, Transplantation proceedings.

[20]  R. C. Johnson,et al.  Sustained expression of high levels of human factor IX from human cells implanted within an immunoisolation device into athymic rodents. , 1998, Human gene therapy.

[21]  Gorka Orive,et al.  History, challenges and perspectives of cell microencapsulation. , 2004, Trends in biotechnology.

[22]  M. Fussenegger,et al.  Towards a fully synthetic substitute of alginate: optimization of a thermal gelation/chemical cross-linking scheme ("tandem" gelation) for the production of beads and liquid-core capsules. , 2004, Biotechnology and bioengineering.

[23]  P. de Vos,et al.  Macrophage depletion improves survival of porcine neonatal pancreatic cell clusters contained in alginate macrocapsules transplanted into rats , 2003, Xenotransplantation.

[24]  L. Nielsen,et al.  Emulsion strategies in the microencapsulation of cells: pathways to thin coherent membranes. , 2005, Biotechnology and bioengineering.

[25]  G. Steil,et al.  Improved Vascularization of Planar Membrane Diffusion Devices following Continuous Infusion of Vascular Endothelial Growth Factor , 2000, Cell transplantation.

[26]  G. Weir,et al.  Long-Term Normoglycemia in Rats Receiving Transplants with Encapsulated Islets , 2005, Transplantation.

[27]  Brian Salmons,et al.  Encapsulated, genetically modified cells producing in vivo therapeutics. , 2004, Current opinion in molecular therapeutics.

[28]  D. Poncelet,et al.  Microencapsulation of silicone oils within polyamide—polyethylenimine membranes as oxygen carriers for bioreactor oxygenation , 2007 .

[29]  F. Shahidi,et al.  Bailey's Industrial oil and fat products , 2005 .

[30]  Heiko Zimmermann,et al.  Long-term graft function of adult rat and human islets encapsulated in novel alginate-based microcapsules after transplantation in immunocompetent diabetic mice. , 2005, Diabetes.

[31]  D. Hunkeler,et al.  Effect of Microcapsule Composition and Short-Term Immunosuppression on Intraportal Biocompatibility , 2005, Cell transplantation.

[32]  C. Colton,et al.  Effect of External Oxygen Mass Transfer Resistances on Viability of Immunoisolated Tissue a , 1997, Annals of the New York Academy of Sciences.

[33]  Efstathios S Avgoustiniatos,et al.  Oxygen diffusion limitations in pancreatic islet culture and immunoisolation , 2002 .

[34]  J. Mcmillan,et al.  Mechanisms of Oxygen Transfer Enhancement during Submerged Cultivation in Perfluorochemical‐in‐Water Dispersions a , 1990, Annals of the New York Academy of Sciences.

[35]  V. Kolb-Bachofen,et al.  Macrophage-generated nitric oxide as cytotoxic factor in destruction of alginate-encapsulated islets. Protection by arginine analogs and/or coencapsulated erythrocytes. , 1993, Transplantation.

[36]  R. Perfetti,et al.  Intrasplenic Transplantation of Encapsulated Genetically Engineered Mouse Insulinoma Cells Reverses Streptozotocin-Induced Diabetes in Rats , 2005, Cell transplantation.

[37]  A. Shapiro,et al.  Five-year follow-up after clinical islet transplantation. , 2005, Diabetes.

[38]  J. Modell,et al.  Diffusion coefficients of molecular oxygen, molecular nitrogen, and carbon dioxide in fluorinated ethers , 1973 .

[39]  O. Korsgren,et al.  Porcine Islet-Like Cell Clusters Cure Diabetic Nude Rats when Transplanted under the Kidney Capsule, But not when Implanted into the Liver or Spleen , 1994, Cell transplantation.

[40]  G. Harb,et al.  Prolonged Survival of Microencapsulated Neonatal Porcine Islets in Mice Treated with a Combination of Anti-CD154 and Anti-LFA-1 Monoclonal Antibodies , 2005, Transplantation.

[41]  S. Matsumoto,et al.  Perfluorocarbon for organ preservation before transplantation. , 2002, Transplantation.

[42]  M Rothmund,et al.  Parathyroid allotransplantation without immunosuppression , 1997, The Lancet.

[43]  P Aebischer,et al.  Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. , 2004, Human gene therapy.

[44]  R. C. Johnson,et al.  Neovascularization of synthetic membranes directed by membrane microarchitecture. , 1995, Journal of biomedical materials research.

[45]  C. Colton,et al.  Tissue Engineering for Insulin Replacement in Diabetes , 2005 .

[46]  P. Aebischer,et al.  Immunoisolated Xenogeneic Chromaffin Cell Therapy for Chronic Pain: Initial Clinical Experience , 1996 .

[47]  N. Déglon,et al.  Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions. , 2004, Human gene therapy.

[48]  R. Bretzel,et al.  Impact of the Perfluorochemical FC43 on Function of Isolated Islets: , 1991, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[49]  A. Haase,et al.  Non-Invasive Evaluation of the Location, the Functional Integrity and the Oxygen Supply of Implants: 19F Nuclear Magnetic Resonance Imaging of Perfluorocarbon-Loaded BA2+-Alginate Beads , 2000, Artificial cells, blood substitutes, and immobilization biotechnology.

[50]  P. de Vos,et al.  Why do microencapsulated islet grafts fail in the absence of fibrotic overgrowth? , 1999, Diabetes.

[51]  Tejal A Desai,et al.  Nanoporous alumina capsules for cellular macroencapsulation: transport and biocompatibility. , 2005, Diabetes technology & therapeutics.

[52]  Y. Bae,et al.  Protection of insulin secreting cells from nitric oxide induced cellular damage by crosslinked hemoglobin. , 2004, Biomaterials.